![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
This patent claims novel inhibitors of the formation of soluble human CD23 and their use in the treatment of diseases associated with overproduction of soluble CD23 (s-CD23) such as autoimmune diseases and allergy. The claimed compounds are also inhibitors of tumour necrosis factor alpha (TNF-α) release. The use for treatment and also for prophylaxis for said diseases has been claimed. The claimed inhibitors are peptidic hydroxamate derivatives.